Understanding Fanconi Renotubular Syndrome 4 with MODY
At a Glance
Fanconi renotubular syndrome 4 is a rare inherited condition caused by an HNF4A gene change. It can cause low blood sugar in newborns, kidney nutrient losses in childhood, and a form of inherited diabetes called HNF4A-MODY later, so coordinated specialist monitoring is important.
Receiving a diagnosis of Fanconi Renotubular Syndrome 4 (FRTS4) can feel overwhelming, especially when it involves multiple systems like the kidneys and the pancreas. This condition is exceptionally rare; much of what we know comes from a single international study of only 25 patients [1]. Because it is so rare, your family may be the first one your local doctors have ever treated with this specific genetic profile.
The Genetic Root: HNF4A
This condition is caused by a change (variant) in the HNF4A gene [1]. This gene acts like a master switch or a “transcription factor.” It provides the instructions for making a protein that tells other genes when to turn on and off in the liver, kidneys, and pancreas [2].
In FRTS4, the genetic change is typically autosomal dominant, meaning only one changed copy of the gene is needed to cause the condition [3]. There is a 50% chance a parent with the variant will pass it to each child. Most patients with this specific kidney-pancreas combination carry a specific variant known as p.Arg85Trp [1].
A Life-Long Journey in Three Phases
This condition is often described as “multi-phasic” because it affects the body differently at different ages. Not every person will experience every phase, but understanding them helps you and your care team stay proactive.
1. The Neonatal Phase (Birth to Newborn)
The first signs often appear before or shortly after birth.
- Macrosomia: Many babies with this variant are born significantly larger or heavier than average [1].
- Hyperinsulinemic Hypoglycemia: This is a condition where the pancreas produces too much insulin (the hormone that lowers blood sugar), leading to dangerously low blood sugar (hypoglycemia) [4].
- Early Management: Newborns often require frequent feedings or intravenous (IV) glucose to keep their sugar levels safe [3]. In some cases, a medication called diazoxide is used to stop the pancreas from overproducing insulin [5].
2. The Renal Phase (Infancy and Childhood)
As the child grows, the focus shifts to the kidneys. This phase is defined by Fanconi Syndrome, a disorder of the proximal tubules (the “sorting centers” of the kidney) [1].
- Wasting: Instead of keeping important nutrients, the kidneys “leak” them into the urine. This includes glucose (glycosuria), amino acids (aminoaciduria), and proteins [1].
- Electrolyte Imbalance: The body may lose too much phosphate and bicarbonate. Low phosphate can lead to rickets (softened, weak bones), while low bicarbonate leads to metabolic acidosis (too much acid in the blood) [6][7].
- Monitoring: Doctors will check for nephrocalcinosis (calcium deposits in the kidneys) and track kidney function, as many children show signs of declining kidney health before age 10 [1].
3. The Diabetic Phase (Adolescence to Adulthood)
Later in life, the same gene variant may cause “not enough” insulin. This leads to a specific type of monogenic diabetes called HNF4A-MODY (MODY1) [4].
- Timing: While the kidney issues usually start in early childhood (median age 1.5 years in the 25-patient cohort), diabetes often develops later [1].
- Treatment: HNF4A-MODY is unique because it often responds very well to a class of oral medications called sulfonylureas, which help the pancreas release more insulin [8][9].
Coordinating Your Care
Because FRTS4 affects different organs at different times, a “medical home” approach is vital. Your child’s care team should ideally include:
- A Pediatric Nephrologist to manage kidney mineral loss and bone health.
- A Pediatric Endocrinologist to monitor blood sugar and growth.
- A Geneticist to help explain the inheritance and test family members if necessary.
Since local doctors may not be familiar with the p.Arg85Trp variant, they may need to consult with rare disease networks or academic research centers that specialize in HNF4A disorders [2]. Your role as a parent is to ensure these specialists are talking to each other, as treatments for the kidneys (like certain supplements) can sometimes affect the management of blood sugar.
Common questions in this guide
What is Fanconi renotubular syndrome 4?
Why can FRTS4 cause low blood sugar in newborns?
What kidney problems can develop in children with FRTS4?
What is HNF4A-MODY, and how is it treated?
How is Fanconi renotubular syndrome 4 inherited?
Which specialists should be involved in FRTS4 care?
Get notified when new evidence is published on Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (9)
- 1
Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.
Emma F, Böckenhauer D, Mallett AJ, et al.
Kidney international reports 2026; (11(8)):106616 doi:10.1016/j.ekir.2026.106616.
PMID: 42440446 - 2
Maturity Onset Diabetes of the Young (MODY): French National Diagnosis and Care Protocol (PNDS, Protocole National de Diagnostic et de Soins).
Dubois-Laforgue D, Donadille B, Ciangura C, et al.
Orphanet journal of rare diseases 2026; (17(Suppl 1)).
PMID: 42227416 - 3
Diazoxide and Continuous Glucose Monitoring as Treatment in a Neonate with Hyperinsulinemic Hypoglycemia due to HNF4A Mutation
Sotiriou G, Xinias S, Diamantidou V, et al.
Journal of clinical research in pediatric endocrinology 2025; doi:10.4274/jcrpe.galenos.2025.2025-4-12.
PMID: 40960027 - 4
A Novel HNF4A Mutation Causing Three Phenotypic Forms of Glucose Dysregulation in a Family.
Chandran S, Rajadurai VS, Hoi WH, et al.
Frontiers in pediatrics 2020; (8()):320 doi:10.3389/fped.2020.00320.
PMID: 32670997 - 5
Exceptional diazoxide sensitivity in hyperinsulinaemic hypoglycaemia due to a novel HNF4A mutation.
Arya VB, Kalitsi J, Hickey A, et al.
Endocrinology, diabetes & metabolism case reports 2019; (2019()).
PMID: 31096182 - 6
Renal Tubular Acidosis.
Bagga A, Sinha A
Indian journal of pediatrics 2020; (87(9)):733-744 doi:10.1007/s12098-020-03318-8.
PMID: 32591997 - 7
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D
Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.
PMID: 35352187 - 8
Maturity-Onset Diabetes of the Young: Rapid Evidence Review.
Kant R, Davis A, Verma V
American family physician 2022; (105(2)):162-167.
PMID: 35166506 - 9
Case Report: Beyond type 1 diabetes: a case of delayed MODY1 diagnosis and successful transition to sulfonylurea therapy.
Gulisano C, Aloi C, Salina A, et al.
Frontiers in medicine 2025; (12()):1590935 doi:10.3389/fmed.2025.1590935.
PMID: 40486195
This page is for informational purposes only and does not constitute medical advice about FRTS4 or HNF4A-MODY. Your child’s pediatric nephrologist, endocrinologist, and geneticist should interpret genetic and laboratory results and guide care.